2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
71
INDUSTRY
68
NIH
5
NETWORK
5
OTHER_GOV
2
INDIV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Retroperitoneal liposarcoma
1
Liposarcoma
1
Leiomyosarcoma
1
Chondrosarcoma
1
Interventions
Proflavine
9
pembrolizumab
2
Tacrolimus
2
Pyridostigmine Bromide
2
Prednisone
2
Microbial Collagenase
2
sargramostim
1
plerixafor
1
pegfilgrastim
1
olaparib
1
nilotinib
1
macimorelin
1
keyhole-limpet hemocyanin
1
ethyl pyruvate
1
compound W
1
blinatumomab
1
Watchful Waiting
1
Uracil
1
Tegafur
1
Surgical Procedures, Operative
1
Steroids
1
Sodium Chloride
1
Sirolimus
1
Salicylates
1
Peptides
1
PM 01183
1
Mycophenolic Acid
1
Monatide (IMS 3015)
1
Mifepristone
1
Methylprednisolone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDIV
×
nilotinib
×
Clear all
NCT02587169
2015-10-27
GEIS-27
Broto, Javier MartÃn, M.D.
Phase 1/2
Unknown
40 enrolled